Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Fluzone®
Biological: GSK investigational vaccine GSK1557482A

First Posted Date: 2009-09-18

Last Posted Date: 2018-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2116

Registration Number: NCT00980005

Locations: 🇺🇸
GSK Investigational Site, Burke, Virginia, United States

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Influenza vaccine GSK2340274A
Biological: Influenza vaccine GSK2340272A

First Posted Date: 2009-09-18

Last Posted Date: 2018-08-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 336

Registration Number: NCT00979407

Locations: 🇩🇪
GSK Investigational Site, Schmiedeberg, Sachsen, Germany

A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients

Phase 2

Withdrawn

Conditions: Arthritis, Rheumatoid

Interventions: Drug: GSK706769
Drug: Placebo

First Posted Date: 2009-09-18

Last Posted Date: 2024-01-22

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00979771

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

Phase 0 Microdose Study

Phase 1

Completed

Conditions: Autoimmune Diseases

Interventions: Drug: [14C]-GSK706769
Drug: Ketoconazole

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00975936

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00976144

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

[11C]Carfentanil PET Study of GSK1521498

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Part A Assessing GSK1521498
Drug: Part C Assessing Naltrexone
Drug: Part B Assessing GSK1521498

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT00976066

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK1614235
Drug: Sitagliptin
Other: Placebo

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 72

Registration Number: NCT00976261

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

Effects of Repeat Dosing of GSK1521498

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Zolpidem or placebo - Hypnotic drug given for sleep disorders
Drug: GSK1521498 or placebo

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 49

Registration Number: NCT00976105

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

Regulatory TYKERB® Tablets PMS

Completed

Conditions: Cancer

Interventions: Drug: TYKERB® tablets

First Posted Date: 2009-09-14

Last Posted Date: 2014-10-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 750

Registration Number: NCT00975988

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: GSK2340273A
Biological: GSK2340274A

First Posted Date: 2009-09-14

Last Posted Date: 2017-12-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 323

Registration Number: NCT00976820

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy